Stoke Therapeutics (STOK) Institutional Ownership
13F filers reported holding 25.9% of Stoke Therapeutics (STOK) shares as of Sep 30, 2026, across 91 filers.
- Held by 13F filers
- 25.9%
- Sep 30, 2026
- 13F filers
- 91
- quarter ended Sep 30, 2026
- 13F value
- $441.0M
- 16.9M shares
- Quarter's fund flow
- Mild distribution
- 6 new · 12 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | Disposed · Open-market sale | 627 | $26.33 | ↗ |
| Oct 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 1,051 | $26.16 | ↗ |
| Sep 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 3,945 | $30.51 | ↗ |
| Sep 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 1,600 | $31.06 | ↗ |
| Aug 18, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | Disposed · Open-market sale | 2,716 | $32.01 | ↗ |
| Aug 18, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | Disposed · Open-market sale | 145 | $32.47 | ↗ |
| Aug 18, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 4,525 | $32.01 | ↗ |
| Aug 18, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 242 | $32.47 | ↗ |
| Aug 18, 2026 | Kaye Edward M. MD | director | Disposed · Open-market sale | 11,930 | $32.01 | ↗ |
| Aug 18, 2026 | Kaye Edward M. MD | director | Disposed · Open-market sale | 637 | $32.47 | ↗ |
| Aug 14, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | Acquired · Option exercise | 6,000 | — | ↗ |
| Aug 14, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | Disposed · Option exercise | 6,000Performance Stock Units | — | ↗ |
| Aug 14, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Acquired · Option exercise | 10,000 | — | ↗ |
| Aug 14, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Option exercise | 10,000Performance Stock Units | — | ↗ |
| Aug 14, 2026 | Kaye Edward M. MD | director | Acquired · Option exercise | 26,250 | — | ↗ |
| Aug 14, 2026 | Kaye Edward M. MD | director | Disposed · Option exercise | 26,250Performance Stock Units | — | ↗ |
| Aug 3, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 5,907 | $28.95 | ↗ |
| Aug 3, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Disposed · Open-market sale | 1,269 | $29.45 | ↗ |
| Jul 16, 2026 | Harrison Seth Loring | director | Disposed · Gift | 29,555Stock Option (Right to Buy) | — | ↗ |
| Jul 16, 2026 | Harrison Seth Loring | director | Acquired · Gift | 29,555Stock Option (Right to Buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Stoke Therapeutics do institutions hold?
13F filers reported holding 25.9% of Stoke Therapeutics' shares as of Sep 30, 2026, across 91 filers.
How many 13F filers hold Stoke Therapeutics?
Stoke Therapeutics was held by 91 13F filers as of Sep 30, 2026.
Not investment advice.

